Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vor Biopharma ( (VOR) ) has shared an update.
Vor Biopharma Inc. held a special meeting on August 25, 2025, where stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the share reserve by 25 million shares and adjusting the annual share reserve increment. Additionally, stockholders approved a reverse stock split and the issuance of shares under outstanding warrants. On August 27, 2025, the company filed a prospectus supplement to register the sale of common stock worth up to $119.7 million, replacing a prior registration statement.
The most recent analyst rating on (VOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biotechnology industry, focusing on the development of cell therapies for cancer treatment. The company is engaged in creating innovative therapies that target hematological malignancies, aiming to improve the outcomes for patients with these conditions.
Average Trading Volume: 17,597,564
Technical Sentiment Signal: Buy
Current Market Cap: $263.5M
For a thorough assessment of VOR stock, go to TipRanks’ Stock Analysis page.